RxDoctor Payments Data

Michael Nash, MD

Family Medicine · Amarillo, TXNPI 1578897765

Payments from drug & device makers

$358in general payments, 2019–2025

Across 22 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$107
  • AstraZeneca$82
  • Insulet Corporation$29
  • Johnson & Johnson$27
  • Sanofi-aventis U.S. LLC$23
  • Merck$17
  • plus $72 from 5 others

What the payments were for

  • Food & beverage$358100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$358 in reported general payments places this provider in the 45th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$5,903
Medicare patients
159
Services billed
415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$78,582
JardianceEmpagliflozin60$77,877
Trelegy ElliptaFluticasone/Umeclidin/Vilanter93$73,835
MounjaroTirzepatide57$68,896
OzempicSemaglutide47$52,257
XareltoRivaroxaban39$37,404
LinzessLinaclotide26$35,366
JanuviaSitagliptin Phosphate23$32,434
EntrestoSacubitril/Valsartan12$22,944
JanumetSitagliptin Phos/Metformin Hcl17$15,389
TrulicityDulaglutide11$12,438
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$10,739
Breo ElliptaFluticasone/Vilanterol14$9,332
SymbicortBudesonide/Formoterol Fumarate28$8,511
Gabapentin341$7,987

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$107$83,167107 claims
PfizerEliquis$12$78,58268 claims
Novo NordiskOzempic, Levemir$13$57,55578 claims
MerckJanuvia, Janumet, Dulera$17$54,02758 claims
Johnson & JohnsonXarelto$27$37,40439 claims
AstraZenecaSymbicort$82$8,51128 claims
Sanofi-aventis U.S. LLCLantus$23$2,77017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →